{"id":7083,"date":"2016-03-08T18:30:50","date_gmt":"2016-03-08T21:30:50","guid":{"rendered":"https:\/\/www.infobioquimica.com\/new\/?p=7083"},"modified":"2016-03-08T18:30:50","modified_gmt":"2016-03-08T21:30:50","slug":"for-lupus-patients-anti-inflammatory-cells-are-maturing-into-wrong-cell-type","status":"publish","type":"post","link":"https:\/\/www.infobioquimica.com\/new\/2016\/03\/08\/for-lupus-patients-anti-inflammatory-cells-are-maturing-into-wrong-cell-type\/","title":{"rendered":"For lupus patients, anti-inflammatory cells are maturing into wrong cell type"},"content":{"rendered":"

A University College London study published on March 8 in\u00a0Immunity<\/em>\u00a0now suggests that for people with lupus, the B cells that regulate inflammation are getting signaled to become pro-inflammatory cells instead. The research, done using human blood samples and genetic profiles, also provides evidence that how a lupus patient responds to treatment is related to their levels of these cellular signals.<\/p>\n

This miscommunication in lupus patients seems to come from an imbalance of three types of immune cells: B cells that produce antibodies to protect the body against foreign microbes (and a main driver of autoimmune disorders); plasmacytoid dendritic cells that produce a molecular signal called interferon-alpha (IFN-\u03b1) that stimulates B cells; and regulatory B cells that suppress excessive immune responses, which come in short supply for lupus patients.<\/p>\n

\u00abOur study shows for the first time that the overproduction of IFN-\u03b1 by hyperactivated plasmacytoid dendritic cells in lupus patients is the consequence of the lack of suppressive regulatory B cells,\u00bb says senior author Claudia Mauri, an immunologist at University College London. \u00abThe uncontrolled production of IFN-\u03b1 causes an increase of antibody-producing B cells and suppresses the division and appearance of regulatory B cells.\u00bb<\/p>\n

The researchers also discovered a potential reason why rituximab, a drug that has been used off-label to treat lupus by depleting the vast majority of circulating B cells, benefits some patients with lupus but not others. The data come from analyzing immune cells and genetic activity from nearly 100 healthy volunteers and 200 people with lupus.<\/p>\n

\u00abAfter treatment, newly formed B cells come back into circulation,\u00bb says lead author Madhvi Menon, a postdoctoral researcher in Mauri’s lab. \u00abOur study suggests that response to rituximab is determined by the presence or absence of an elevated IFN-\u03b1-related gene activity,\u00bb she says. \u00abThus, only in patients that have a normal IFN-\u03b1 signature do the newly repopulated B cells successfully mature into regulatory B cells.\u00bb<\/p>\n

The results suggest that lupus patients should be tested for this IFN-\u03b1-related gene signature prior to treatment with rituximab. \u00abThis would be an important step towards personalised medicine for the treatment of lupus,\u00bb Mauri says.<\/p>\n

Source:\u00a0<\/strong>www.biocompare.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A University College London study published on March 8 in\u00a0Immunity\u00a0now suggests that for people with lupus, the B cells that regulate inflammation are getting signaled to become pro-inflammatory cells instead. The research, done using human blood samples and genetic profiles, also provides evidence that how a lupus patient responds to treatment is related to their […]<\/p>\n","protected":false},"author":1,"featured_media":7084,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"twitterCardType":"","cardImageID":0,"cardImage":"","cardTitle":"","cardDesc":"","cardImageAlt":"","cardPlayer":"","cardPlayerWidth":0,"cardPlayerHeight":0,"cardPlayerStream":"","cardPlayerCodec":"","footnotes":""},"categories":[655],"tags":[5513,5509,5523,5507,5515,5521,5525,5519,5517,5511],"class_list":["post-7083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-ingles","tag-antibodies","tag-b-cells","tag-ifn--related-gene","tag-immune-cells","tag-inflammation","tag-interferon-alpha","tag-lupus-en","tag-plasmacytoid-dendritic-cells","tag-pro-inflammatory-cells","tag-regulatory-b-cells"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/7083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/comments?post=7083"}],"version-history":[{"count":1,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/7083\/revisions"}],"predecessor-version":[{"id":7085,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/7083\/revisions\/7085"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/media\/7084"}],"wp:attachment":[{"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/media?parent=7083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/categories?post=7083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infobioquimica.com\/new\/wp-json\/wp\/v2\/tags?post=7083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}